ETFs in Focus on Bayer’s Bet on Gene Therapy – Zacks.com
Posted: November 3, 2020 at 1:53 am
Merger and acquisition activities have heated up in recent months and the niche spaces are in the limelight. After the telemedicine industry, gene therapy stocks jumped on the bandwagon. Gene therapy is a technique that uses genes to treat or prevent disease.
German drugmaker Bayer has made a big bet on gene therapy by announcing the acquisition of U.S. biotech firm Asklepios BioPharmaceutical for as much as $4 billion. The proposed acquisition will provide Bayer access to the adeno-associated virus (AAV) gene therapy platform and a pipeline led by clinical-phase treatments for Parkinsons, Pompe disease and congestive heart failure. Notably, AAV therapies offer improved efficacy, immune response, and tissue and organ specificity.
Additionally, the transaction will complements Bayers 2019 acquisition of BlueRock Therapeutics and advances its efforts to create platforms with the potential to have an impact on multiple therapeutic areas (read: Genomics ETFs Surge on Nobel Prize for Gene-Editing Pioneers).
Under the terms of the deal, Bayer will pay an upfront consideration of $2 billion and potential success-based milestone payments of up to $ billion. About 75 % of the potential milestone-based contingent payments are expected to be due during the course of the next five years and the remaining amount thereafter.
The deal, pending regulatory approvals, is expected to close during the fourth quarter of 2020. Once the deal closes, Bayer will allow Asklepios, known as AskBio, to operate autonomously as part of a new cell and gene therapy unit in a bid to preserve its entrepreneurial culture. The cell and gene therapy unit will bundle Bayer's activities in this area moving forward in order to establish an innovation ecosystem for the participating partners, the German company said (see: all the Healthcare ETFs here).
The proposed deal will provide a boost to the gene therapy industry. Below, we have highlighted four ETFs that are expected to benefit from Bayers entrance into the gene therapy space:
ARK Genomic Revolution Multi-Sector ETF (ARKG - Free Report)
This actively managed ETF is focused on companies that are likely to benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments, and advancements in genomics into their business. With AUM of $2.9 billion, the fund holds 47 stocks in its basket and has 0.75% in expense ratio. It trades in an average daily volume of 978,000 shares (read: 4 Sector ETFs That Have Doubled This Year).
Invesco Dynamic Biotechnology & Genome ETF (PBE - Free Report)
This fund follows the Dynamic Biotech & Genome Intellidex Index and provides exposure to companies engaged in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes and companies that benefit significantly from scientific and technological advances in biotechnology and genetic engineering and research. It holds 31 stocks in its basket and charges 57 bps in annual fees. The ETF has managed $229.9 million in its asset base while trades in a light volume of 6,000 shares per day. Expense ratio comes in at 0.57%. The product has a Zacks ETF Rank #3 (Hold) with a High risk outlook.
Global X Genomics & Biotechnology ETF (GNOM - Free Report)
This product seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics and biotechnology. It follows the Solactive Genomics Index, holding 40 stocks in its basket. This ETF has accumulated $68 million in its asset base and charges 50 bps in annual fees. It trades in average daily volume of 31,000 shares (read: Why You Should Invest in Genomics ETFs).
iShares Genomics Immunology and Healthcare ETF (IDNA - Free Report)
This ETF provides access to companies at the forefront of genomics and immunology innovation by tracking the NYSE FactSet Global Genomics and Immuno Biopharma Index. Holding 46 stocks in its basket, the fund has gathered $166.2 million in AUM and trades in moderate average daily volume of 58,000 shares. It charges 47 bps in annual fees.
Zacks free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
Here is the original post:
ETFs in Focus on Bayer's Bet on Gene Therapy - Zacks.com
- Advarra Announces New Gene Therapy Ready Site Network - PRNewswire - January 23rd, 2021
- UK biotech Ixaka scores additional funding for cell and gene therapy research - PharmaTimes - January 23rd, 2021
- Neurogene and University of Edinburgh Announce Research Collaboration to Advance Next Generation Gene Therapies - Business Wire - January 23rd, 2021
- Cure Genetics Collaborates with Boehringer Ingelheim to Develop Novel AAV Vectors Enabling the Next-generation Liver-targeted Gene Therapy - BioSpace - January 23rd, 2021
- Cancer Gene Therapy Market Size Study with COVID-19 Impact 2020, Share, Industry Analysis, Growth, Segmentation and Forecast to 2026 KSU | The... - January 23rd, 2021
- Chinese scientists develop new gene therapy that can delay the aging process - National Post - January 23rd, 2021
- Gene therapy developed to delay ageing - The Financial Express - January 23rd, 2021
- Bone Therapeutics provides fourth quarter 2020 business update and 2021 outlook - GlobeNewswire - January 23rd, 2021
- How 2 scientific pioneers teamed up to run AskBio, Bayer's new gene therapy division - BioPharma Dive - January 22nd, 2021
- Neurogene in tie up with university to advance gene therapy technologies - BioPharma-Reporter.com - January 22nd, 2021
- Cell and Gene Therapy Consumables Market 2020 Key Manufacturers, Development Trends and Competitive Analysis 2026 KSU | The Sentinel Newspaper - KSU... - January 22nd, 2021
- New Research Grant Seeks to Clarify the Role Genes Play in Modulating Inflammation - NYU Langone Health - January 22nd, 2021
- Lilly Completes Acquisition of Prevail Therapeutics - BioSpace - January 22nd, 2021
- Cancer Gene Therapy Market : Future Prospects With Covid-19 Impact Analysis 2027 | Top Players- Adaptimmune, GlaxoSmithKline plc, bluebird bio, Inc -... - January 22nd, 2021
- Global Gene Therapy Market Worth $38.41 Million by 2025- Exclusive Report by Fior Markets - PharmiWeb.com - January 22nd, 2021
- Covance boosts Franklin to lead its cell and gene therapy unit - FierceBiotech - January 22nd, 2021
- Explore why Cancer Gene Therapy Market is thriving by 2025 with top key players like Genelux Corporation, Cell Genesys, Advantagene, GenVec,... - January 22nd, 2021
- The global transient protein expression market is expected to reach US$ 983.10 million by 2027 from US$ 660.00 million in 2019 - GlobeNewswire - January 22nd, 2021
- Regenerative Medicine Market Size Worth $23.57 Bn By 2027; High demand for 3D bioprinting of tissues and organs to better understand their mechanism... - January 22nd, 2021
- Cancer Gene Therapy Market Segmentation, Parameters, Prospects 2021 And Forecast Research Report To 2027 - The Courier - January 22nd, 2021
- Taysha Gene Therapies Receives Rare Pediatric Disease and Orphan Drug Designations for TSHA-105 for the Treatment of Epilepsy Caused by SLC13A5... - January 22nd, 2021
- The Global Cancer Gene Therapy Market is expected to grow by $ 2.96 bn during 2021-2025 progressing at a CAGR of 20% during the forecast period -... - January 22nd, 2021
- Gene Therapy Technologies Market Estimated to Experience a Hike in Growth by 2021 2026: Bluebird bio, Adaptimmune, GlaxoSmithKline - KSU | The... - January 22nd, 2021
- Unleashing the cancer-fighting gene TP53 in leukemia with a novel combination treatment - FierceBiotech - January 22nd, 2021
- Big Boom in Gene Therapy Market Detailed Analysis of Current and Future Industry Figures till 2028 |Novartis AG, Gilead Sciences, Inc., UniQure N.V.,... - January 22nd, 2021
- Gene therapy developed to delay ageing - The Financial Express BD - January 22nd, 2021
- Biogen and ViGeneron to Collaborate on Ophthalmic Gene Therapy Development - JD Supra - January 9th, 2021
- With decades in gene therapy under his belt, Ronald Crystal launches new venture with up to 18 candidates in the pipe - Endpoints News - January 9th, 2021
- GeneOne to supply plasmid DNA therapy worth $2 million to US - Korea Biomedical Review - January 9th, 2021
- Fujifilm triples down on viral vector manufacturing with new $40M Boston site - FiercePharma - January 9th, 2021
- REGENXBIO Announces Update on RGX-314 and Pivotal Program for the Treatment of Wet AMD and New Gene Therapy Program for the Treatment of Duchenne... - January 9th, 2021
- Gene therapy for tuberous sclerosis complex type 2 in a mouse model by delivery of AAV9 encoding a condensed form of tuberin - Science Advances - January 9th, 2021
- Chinese researchers discover new anti-aging gene therapy - The Star Online - January 9th, 2021
- Engineered stem cells that evade immune detection could boost cell therapy and I-O - FierceBiotech - January 9th, 2021
- article image Advances in gene therapy to help paralysis - Digital Journal - January 9th, 2021
- Oncternal Therapeutics and Karolinska Institutet Establish Collaboration for Research and Development of ROR1-targeting CAR-T and CAR-NK Cell... - January 9th, 2021
- AllStripes Announces Collaboration with Taysha Gene Therapies for SURF1-Associated Leigh Syndrome Program - Business Wire - January 9th, 2021
- Regenerative Medicine Market to Reach Valuation US$ 23.7 Bn by 2027 - GlobeNewswire - January 9th, 2021
- Global Cell and Gene Therapy Market Report 2020-2030: COVID-19 Impacts, Growth and Changes - GlobeNewswire - January 9th, 2021
- Mana joins the hectic fight against solid tumors with an 'off-the-shelf' candidate angling for an IND this year - Endpoints News - January 9th, 2021
- Dewpoint forges another big pharma partnership and a potential rivalry - BioPharma Dive - January 9th, 2021
- IsoPlexis scores big backer for personalized protein 'barcodes' as Perceptive jumps on board new funding round - Endpoints News - January 9th, 2021
- Global Soft Tissue Repair Market- Featuring 3M Co., Arthrex Inc., and Baxter International Inc. Among Others - Business Wire - January 9th, 2021
- Looking to solve the solid tumor puzzle box, Carisma aims to take 'CAR-M' groundbreaker into early-stage trial - Endpoints News - January 9th, 2021
- DiCE gets its 'library' card ready as it speeds development of DNA database-derived molecules with more investor cash - Endpoints News - January 9th, 2021
- Study: Too few with high blood pressure tested for hormone disorder - UPI News - December 30th, 2020
- These Families Raised Millions To Fund Treatment For Their Kids' Genetic Disorders. It Hasn't Happened. - KCUR - December 26th, 2020
- Taysha Gene Therapies Announces Queen's University's Receipt of Clinical Trial Application Approval from Health Canada for Phase 1/2 Clinical Trial of... - December 26th, 2020
- After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream - PMLiVE - December 26th, 2020
- Regenerative Medicine in Pharma 2020 - Opportunities, Challenges, and Unmet Needs - GlobeNewswire - December 26th, 2020
- Gene Therapy for Rare Disease Market Prospects Pinpoint Higher Traction from Developed Nations during 2020-2026 | Coherent Market Insights | Kite... - December 26th, 2020
- Gene Therapy Market Regions, Type and Application, Futuristic Study - Factory Gate - December 26th, 2020
- News briefing: Merck buys into A2's T cell therapy platform; Small Soligenix reports PhIII fail in head and neck cancer - Endpoints News - December 26th, 2020
- Biopharma Money on the Move: December 16-22 - BioSpace - December 26th, 2020
- Ziopharm Oncology Announces Clearance of Taiwan's First IND of Non-viral CAR-T for the Treatment of Relapsed CD19+ Leukemias and Lymphomas -... - December 26th, 2020
- Ocugen Establishes Vaccine Scientific Advisory BoardLeading experts to evaluate the clinical and regulatory path to approval in the US market of... - December 26th, 2020
- Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-715 in Combination with Nirogacestat in... - December 26th, 2020
- Gyroscope Therapeutics and the University of Pennsylvania Announce Research Agreement to Develop Gene Therapies for Serious Eye Diseases - Business... - December 19th, 2020
- Every Patient Treated With CRISPR Gene Therapy for Blood Diseases Continues to Thrive, More Than a Year On - Good News Network - December 19th, 2020
- The next generation of gene therapy for rare diseases forges ahead as developers weather hurdles - FierceBiotech - December 19th, 2020
- Atsena Therapeutics Raises $55 Million Series A Financing to Advance LCA1 Gene Therapy Clinical Program, Two Preclinical Assets, and Novel Capsid... - December 19th, 2020
- Repurposing a proven gene therapy approach to treat, prevent COVID-19 - Penn Today - December 19th, 2020
- Locanabio Raises $100 Million to Advance RNA-Targeted Gene Therapies - BioSpace - December 19th, 2020
- Technical Report on Gene Therapy in Oncology Market 2021 - LionLowdown - December 19th, 2020
- Biopharma Money on the Move: December 9-15 - BioSpace - December 19th, 2020
- Global Gene Expression Market Analysis and Forecasts - A $6.78 Billion Market by 2027 - PRNewswire - December 19th, 2020
- Though Promising, Gene Therapies Face Durability And Reimbursement Headwinds - Forbes - December 17th, 2020
- Lilly scores gene therapy programme in $1bn Prevail Therapeutics acquisition deal - PMLiVE - December 17th, 2020
- Gene Therapy in One Eye Improves Vision in Both Eyes - The Scientist - December 17th, 2020
- Gene Therapy Market Worth USD 35.67 Billion at 33.6% CAGR; Rising Prevalence of Spinal Muscular Atrophy to Augment Growth: Fortune Business Insights -... - December 17th, 2020
- Health Canada approves Zolgensma, the one-time gene therapy for pediatric patients with spinal muscular atrophy (SMA) - Canada NewsWire - December 17th, 2020
- Global Gene Therapy Market Report 2020-2030 Featuring Novartis, Bluebird Bio, Spark Therapeutics, Audentes Therapeutics, Voyager Therapeutics,... - December 17th, 2020
- Passage Bio Invests In Gene Therapy Manufacturing R&D Site - Contract Pharma - December 17th, 2020
- Experimental Therapy Injected in One Eye Unexpectedly Improves Vision in The Other - ScienceAlert - December 17th, 2020
- After leaving Wall Street to launch a gene therapy upstart, Rachel McMinn nabs $115M to drive her first candidate to the clinic - Endpoints News - December 17th, 2020
- They thought their gene therapy failed. Instead, it spawned a medical mystery - Endpoints News - December 17th, 2020
- Cell And Gene Therapy Market Trends, Growth, Size, Analysis and Forecast by 2024 with Top Players: JW CreaGene,Vericel,Tego Sciences,GC... - December 17th, 2020
- Single gene therapy injection surprisingly boosts vision in both eyes - New Atlas - December 17th, 2020
- Cell and Gene Therapy Global Market Report 2020-30: COVID-19 Growth and Change - GlobeNewswire - December 17th, 2020
- Cancer Gene Therapy Market Global Opportunities and Industry Share Expected Surpass $2082 Million b - PharmiWeb.com - December 17th, 2020